Cebaracetam – (113957-09-8)

Cebaracetam is an experimental drug of the racetam group, described as a nootropic, which was never marketed.

It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and a derivative of RGPU-95. The mechanism of action of cebaracetam is undefined or unknown.

Developed by Novartis for the treatment of cognitive disorders in the 1990s, it reached phase 2 clinical trials before development was discontinued in 1995.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Cebaracetam is an experimental drug of the racetam group, described as a nootropic, which was never marketed.

It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and a derivative of RGPU-95. The mechanism of action of cebaracetam is undefined or unknown.

Developed by Novartis for the treatment of cognitive disorders in the 1990s, it reached phase 2 clinical trials before development was discontinued in 1995.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Cebaracetam
https://pubchem.ncbi.nlm.nih.gov/compound/65919
https://www.medkoo.com/products/58003
https://writeupcafe.com/effects-of-cebaracetam-rgpu-95-on-cognitive-function/

Other Names	Cebaracetam [INN], UNII-Q25MNP6OC1, Q25MNP6OC1
IUPAC Name	4-[2-[4-(4-chlorophenyl)-2-oxopyrrolidin-1-yl]acetyl]piperazin-2-one
CAS	113957-09-8
Molecular Weight	335.78
Molecular Formula	C16H18ClN3O3
SMILES	C1CN(CC(=O)N1)C(=O)CN2CC(CC2=O)C3=CC=C(C=C3)Cl

Products

Consulting & Services

Check Out Our Research And Updates

Cebaracetam – (113957-09-8)

Cebaracetam is an experimental drug of the racetam group, described as a nootropic, which was never marketed.

It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and a derivative of RGPU-95. The mechanism of action of cebaracetam is undefined or unknown.

Developed by Novartis for the treatment of cognitive disorders in the 1990s, it reached phase 2 clinical trials before development was discontinued in 1995.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Cebaracetam
https://pubchem.ncbi.nlm.nih.gov/compound/65919
https://www.medkoo.com/products/58003
https://writeupcafe.com/effects-of-cebaracetam-rgpu-95-on-cognitive-function/

About Us

Products

Services

Quick Contact

Check Out Our Research And Updates

Cebaracetam – (113957-09-8)

Cebaracetam is an experimental drug of the racetam group, described as a nootropic, which was never marketed.

It is a chlorinated acetylpiperazine-substituted analogue of phenylpiracetam and a derivative of RGPU-95. The mechanism of action of cebaracetam is undefined or unknown.

Developed by Novartis for the treatment of cognitive disorders in the 1990s, it reached phase 2 clinical trials before development was discontinued in 1995.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/Cebaracetam https://pubchem.ncbi.nlm.nih.gov/compound/65919 https://www.medkoo.com/products/58003 https://writeupcafe.com/effects-of-cebaracetam-rgpu-95-on-cognitive-function/

Related products

Quick Contact

https://en.wikipedia.org/wiki/Cebaracetam
https://pubchem.ncbi.nlm.nih.gov/compound/65919
https://www.medkoo.com/products/58003
https://writeupcafe.com/effects-of-cebaracetam-rgpu-95-on-cognitive-function/